Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery

被引:72
作者
Boland, GP
Chan, KC
Knox, WF
Roberts, SA
Bundred, NJ
机构
[1] Univ S Manchester Hosp, Dept Surg, Manchester M20 8LR, Lancs, England
[2] Univ S Manchester Hosp, Dept Pathol, Manchester M20 8LR, Lancs, England
[3] Univ Manchester, Sch Epidemiol & Hlth Sci, Biostat Grp, Manchester, Lancs, England
关键词
D O I
10.1002/bjs.4051
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The Van Nuys Prognostic Index (VNPI), an algorithm based on tumour size, tumour grade, presence of necrosis and excision margin width, is claimed to predict local recurrence after breast-conserving surgery for ductal carcinoma in situ (DCIS). The aim of this study was to examine the validity of the VNPI in a UK population. Methods: Clinicopathological data, including VNPI subgroups, for 237 patients who had breast-conserving operations for DCIS were examined. Multivariate data analysis was performed using a Cox regression model to examine the independence and relative importance of different variables in predicting recurrence, and to compare the data with those used in derivation of the VNPI. Results: The median follow-up was 47 months. There were 37 ipsilateral local recurrences. Excision margin width (P<0.001) and tumour grade (by Van Nuys grading (P=0.014) or simple nuclear grading (P=0.004)) were the only independent risk factors for local recurrence. Excision margin width had three times more power than grade in predicting local recurrence. Subgrouping data by VNPI score predicted recurrence-free survival (P<0.001), but stratified 78 per cent of patients into a group with a moderate risk of local recurrence. Conclusion: Excision margin width is the most important predictor of local recurrence after breast-conserving surgery for DCIS. The VNPI lacked discriminatory power for guiding further patient management.
引用
收藏
页码:426 / 432
页数:7
相关论文
共 32 条
[1]   Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853 [J].
Bijker, N ;
Peterse, JL ;
Duchateau, L ;
Julien, JP ;
Fentiman, IS ;
Duval, C ;
Di Palma, S ;
Simony-Lafontaine, J ;
de Mascarel, I ;
van de Vijver, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2263-2271
[2]  
Boyages J, 1999, CANCER, V85, P616, DOI 10.1002/(SICI)1097-0142(19990201)85:3<616::AID-CNCR12>3.3.CO
[3]  
2-Z
[4]  
Chan KC, 2001, CANCER, V91, P9, DOI 10.1002/1097-0142(20010101)91:1<9::AID-CNCR2>3.0.CO
[5]  
2-E
[6]   Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation [J].
Chan, KC ;
Knox, WF ;
Gandhi, A ;
Slamon, DJ ;
Potten, CS ;
Bundred, NJ .
BRITISH JOURNAL OF SURGERY, 2001, 88 (03) :412-418
[7]   Relationship between the size and margin status of ductal carcinoma in situ of the breast and residual disease [J].
Cheng, L ;
AlKaisi, NK ;
Gordon, NH ;
Liu, AY ;
Gebrail, F ;
Shenk, RR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (18) :1356-1360
[8]   Application of the Van Nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examinated by serial macroscopic sectioning:: Practical considerations [J].
de Mascarel, I ;
Bonichon, F ;
MacGrogan, G ;
de Lara, CT ;
Avril, A ;
Picot, V ;
Durand, M ;
Mauriac, L ;
Trojani, M ;
Coindre, JM .
BREAST CANCER RESEARCH AND TREATMENT, 2000, 61 (02) :151-159
[9]   Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program [J].
Ernster, VL ;
Barclay, J ;
Kerlikowske, K ;
Wilkie, H ;
Ballard-Barbash, R .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (07) :953-958
[10]   Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J].
Fisher, B ;
Bryant, J ;
Wolmark, N ;
Mamounas, E ;
Brown, A ;
Fisher, ER ;
Wickerham, DL ;
Begovic, M ;
DeCillis, A ;
Robidoux, A ;
Margolese, RG ;
Cruz, AB ;
Hoehn, JL ;
Lees, AW ;
Dimitrov, NV ;
Bear, HD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2672-2685